This Week in Oncology — May 21, 2026

Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new frontiers for antibody-drug conjugates, refinements in perioperative therapy, and major updates in tough-to-treat cancers. Let's dive in.
This week's papers:
• Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42167437)
• Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer. — Cancer Cell 2026 (pubmed.ncbi.nlm.nih.gov/42167230)
• Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42166704)
• Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42166701)
• Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial. — JAMA Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42166134)
• Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42162665)
• Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42160714)
• A long-term image-derived AI-based risk model for primary prevention of breast cancer in individuals at high risk. — Science Translational Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42160452)
• Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance. — Nature Cancer 2026 (pubmed.ncbi.nlm.nih.gov/42156983)
• Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42150145)
Listen at AudioScholar (audioscholar.cc/episode/ktndcphe4q)